In this work, we reviewed the recently published preclinical and clinical studies on UC-MSCs as a therapeutic method and advances towards their use through DFPP to identify new treatment options for patients with SLE.
Treatment of SLE Patients co-treated with DFPP & UC-MSCs
Systemic lupus erythematosus (SLE) is an immune-mediated syndrome where the immune system does not differentiate between self and nonself, leading to rampant destruction of tissues. SLE can involve the skin, joints, kidneys, blood vessels, nervous system and many other organ systems. Due to the very variable nature of lupus, treatment should always be tailored according to disease severity, organ involvement, blood results, markers of inflammation, medication history and specialists opinion.
Management of SLE is tailored according to disease activity and organ involvement; standard options include hydroxychloroquine, glucocorticoids, immunosuppressive drugs, calcineurin inhibitors, and biologics. Kidney-focused guidelines for lupus nephritis also highlight structured immunosuppressive care and tight monitoring.
In addition to conventional lupus treatment, some patients seek advanced supportive treatments like stem cell therapy with UC-MSCs and Double Filtration Plasmapheresis or DFPP therapy. These techniques should not be advertised as a solution, although they may help in carefully selected cases.
What Are UC-MSCs in SLE Care?
UC-MSCs (umbilical cord-derived mesenchymal stem/stromal cells) have been studied for their immune-modulating, anti-inflammatory and tissue-supporting signaling characteristics. So in SLE, UC-MSC may not directly replenish lost organs. Their functional capacity originates from their interactions with the immune system mediated via cytokines, growth factors, extracellular vesicles and other paracrine signaling events.
Reports from MSC trials in SLE and lupus nephritis have shown promising safety data, as well as potential efficacy information concerning disease activity and renal-related outcomes, but larger controlled studies are still needed due to the developing nature of the evidence.
Possible Benefits of Have UC-MSC for SLE
Supporting immune balance
Immune dysregulation drives SLE. It has been noted that UC-MSCs regulate activities of immune cells like T cells, B cells and macrophages along with inflammatory mediators as well.
Helping reduce excessive inflammatory signaling
These UC-MSCs might release pro-osteo-immunoregulatory signals that contribute to setting a less inflammatory milieu. This may prove to be significant for those patients who had active chronic inflammation.
Supporting tissue-repair signaling
Chronic Lupus Inflammation can target tissues and organs these findings show that UC-MSCs may facilitate repair signaling and improve the microenvironments surrounding injured tissues.
Supporting quality of life goals
The objective is to promote general health, efficiency, inflammatory treatment and satisfaction some patients along with routine lupus therapy.
What Is DFPP Therapy for SLE?
Double Filtration Plasmapheresis (DFPP) is a powerful blood washing system that selectively separates plasma and reduces larger circulating substances. In autoimmune conditions including SLE, DFPP may be used in some cases due to its ability for removal of circulating immune-related factors such as autoantibodies, immune complexes and inflammatory mediators.
DFPP combined with immunosuppressive treatment of lupus nephritis has been explored as an adjunct therapy, with improvements in inflammatory markers and clinical parameters noted in specific population groups.
Possible Benefits of DFPP Therapy for SLE
Reducing circulating autoimmune burden
Conclusions: Selected plasma characteristics that are relevant for autoimmune activity may be selectively lowered with DFPP.
Supporting inflammatory control
DFPP may reduce the inflammatory load in a subset of patients by filtering specific mediators.
Supporting kidney-related lupus management
DFPP can be part of a medically managed program for patients with lupus nephritis or heavy immune-complex burden.
Preparing body for regenerative support
Therefore, DFPP might facilitate a favorable internal environment prior to UC-MSC infusion by removing some inflammatory and immune-related factors from the circulation.
Figure 1: Supportive Clinical Roles of DFPP Therapy in Systemic Lupus Erythematosus
Why DFPP Therapy in Combination with UC-MSCs?
Since combination therapy are often better than a single therapy in treating some diseases, design the method of treatment leave it to two supportive directions for SLE approches: DFPP and stem cell UC-MSC.
DFPP acts initially by decreasing defined circulating autoimmunological and inflammatory markers. This might even help reduce the automatic immune stress within the blood stream.
After encapsulation UC-MSCs action via immune-modulatory and regenerative signals. They are involved in maintaining immune homeostasis, mediating inflammation while collaborating with the tissue repair process.
Thus, DFPP may set up the internal environment of patient, while UC-MSCs may serve as supportive biological signals following filtration. This combination approach may be especially beneficial in select patients with high levels of inflammation, autoantibody activity, or immune-complex burden.
Combined Potential Benefits
A work vessel DFPP + UC-MSCs protocol for SLE may facilitate:
Immune balance
Reduction of selected inflammatory burden
A cleaner internal environment prior to UC-MSC infusion
Increased inherent predisposition to UC-MSC signaling
Tissue-repair support
Overall well-being and quality of life
A more comprehensive supportive plan in addition to standard treatment for lupus
We have to clarify that using that combination does not mean replacing the standard lupus treatment. It could, however, be regarded as a special assistant alternative for chosen patients at the behest of doctors.
Who May Be Suitable?
This could be an option for some SLE patients based on:
Type and severity of lupus
Status of lupus nephritis or kidney involvement
Autoantibody and immune-complex activity
Inflammatory markers
Medication history
Infection screening
Liver and kidney function
Overall health condition
Doctor’s assessment
It may also effective for patients with active infection, unstable medical conditions, severe anemia and bleeding risk as well as other contraindications to medication should be screened by a clinician before these interventions are initiated.
Conclusion
The approach of UC-MSCs with SLE is immune modulation, supporting inflammation and tissue-repair signaling. In SLE, DFPP therapy aims to remove specific circulating autoimmune and inflammatory factors. DFPP may create a more favorable internal environment when given in combination with UC-MSCs, which can provide supportive regenerative and immunomodulatory signaling.
In selected patients with systemic lupus erythematosus, this combined approach might provide a more accurate supportive treatment in addition to standard rheumatology care. Yet, any treatment should be individualized, medically supervised and realistically based.